Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

Cutaneous Squamous Cell Carcinoma Clinical Trial

— MATISSE  

Official title:

Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Patients Prior to Standard of Care Surgery; the MATISSE Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04620200
• Other study ID #: N20MAT
• Status: Recruiting
• Phase: Phase 2
• Start date: August 11, 2020
• Est. completion date: November 1, 2024

Study information

• Verified date: October 2022
• Source: The Netherlands Cancer Institute
• Contact: Thomas Boere, MD
• Phone: + 31 0205129111
• Email: th.boere[@]nki.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of standard of care(surgery ± radiotherapy).in patients with cutaneous squamous cell carcinoma.

Description:

This is an investigator-initiated randomized non-comparative phase II trial consisting of 40 patients with resectable stage III-IVa CSCC randomized 1:1 to ARM A: 2 courses of nivolumab 3 mg/kg in week 0 and 2, or ARM B: 2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0. Both treatment arms are neo-adjuvant and applied prior to standard of care (consisting of surgery at week 4 with or without adjuvant radiotherapy).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: November 1, 2024
• Est. primary completion date: November 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 years or older.

2. Patient is able to understand and comply with the protocol requirements and has signed the informed consent form.

3. World Health Organization (WHO) Performance Status 0 or 1 (Appendix B).

4. Patients with histologically or cytologically confirmed, primary or recurrent stage III-IVA CSCC of all body sites.

OR

Patients with histologically or cytologically proven stage I-II CSCC, only in the case of:

• Presence of multifocal disease for which extensive and/or mutilating surgery is necessary (e.g. near-total scalp resection).

• Situated in an anatomical localization that necessitates extensive and/or mutilating surgery (e.g. orbital exenteration).

5. Eligible for standard-of-care, curatively intended surgery with or without adjuvant radiotherapy.

6. Screening laboratory values must meet the following criteria: WBC = 2.0x109 /L, Neutrophils =1.5x109 /L, Platelets =100 x109 /L, Hemoglobin =5.5 mmol/L, Creatinine =1.5x ULN, AST = 1.5 x ULN, ALT = 1.5 x ULN, Bilirubin =1.5 X ULN (except subjects with Gilbert Syndrome, who are eligible when total bilirubin < 3.0 mg/dL).

7. Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. They should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of the investigational drug.

8. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) prior to the start of nivolumab or nivolumab + ipilimumab.

9. Men who are sexually active with WOCBP must use a contraceptive method with a failure rate of less than 1% per year and will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product. Surgically sterile or azoospermic men do not require aforementioned contraception.

Exclusion Criteria:

1. Distantly metastasized (stadium IVb) CSCC.

2. SCC localized in a mucosal surface (i.e. anus, vulva, penis or mucosal portion of lip).

3. Patients for whom SOC consists of definitive (brachy)radiotherapy.

4. Primary or recurrent CSCC appearing in an area that has been previously irradiated.

5. Prior anti-CTLA4 or anti-PD1 immunotherapy.

6. Active human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

7. A positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C antibody (HCV Ab).

8. Subjects with any active autoimmune disease or a documented history of autoimmune disease, except for:

• Subjects with vitiligo

• Resolved childhood asthma/atopy

• Residual hypothyroidism due to an autoimmune condition requiring only hormone replacement

• Psoriasis not requiring systemic treatment

• Any condition not expected to recur in the absence of an external trigger.

9. Underlying medical conditions that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or AE.

10. A concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;

11. Pregnant or nursing.

12. A history of allergy to study drug components and/or a history of severe hypersensitivity to any monoclonal antibody.

13. Use of other investigational drugs 30 days before study drug administration and 5 half times before study inclusion.

14. Use of prohibited medication at start of study period

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Cutaneous Squamous Cell Carcinoma

Intervention

Drug:
• Nivolumab
3mg/kg
• Ipilimumab
1mg/kg

Locations

Country	Name	City	State
Netherlands	NKI-AVL	Amsterdam	Noord Holland

Sponsors (1)

Lead Sponsor	Collaborator
The Netherlands Cancer Institute

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Histopathological response rate at standard of care	The proportion of viable tumor cells left in the resected specimen, to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of SOC (surgery ± RT).	At time of standard of care at week 4
Secondary	Sensitivity and specificity of tumor biopsies, clinical photography, FDG-PET and (functional)MRI compared to the histopathological tumor response to neo-adjuvant immunotherapy	Histopathological tumor response to neo-adjuvant immunotherapy as measured in the tumor resection specimen will be compared to the tumor response as measured via serial tumor biopsies, the tumor biopsy at time of surgery and imaging (clinical photography, FDG-PET and (f)MRI). Histopathologic response in the tumor biopsies will be defined similarly as histopathologic response in the resected specimen. Response at imaging studies will be measured as follows: Clinical photography via specific clinical observation criteria, FDG-PET via RECIST 1.1 criteria and % change in TLG or MTV and (f)MRI via RECIST 1.1	At time of standard of care at week 4
Secondary	Numbers of participants without significant delay (>1 week) or cancelation of SOC surgery due to immune-related toxicity		At time of standard of care at week 4
Secondary	Recurrence free survival (RFS) at 2 years FU of responders versus non-responders to neo-adjuvant ICI		At 2-years follow up
Secondary	Overall survival (OS) at 2 years FU of responders versus non-responders to neo-adjuvant ICI		At 2-years follow up
Secondary	The number of patients with AE (rate and type) acoording to NCI CTCAE v.5.0 up to 2 years FU after SOC		At 2-years follow up
Secondary	Clinical response of potentially additional AK surface areas after ICI identified by digital clinical photography on day 0, day 14, day 28 and every 6 months during FU up to 2 years.		On day 0, day 14, day 28 (at time of surgery) and every 6 months during FU up to 2 years.
Secondary	Quality of life as measured by EORTC QLQ-C30	Rated on a Likert-type scale from one (never) to four (almost always), to evaluate different domains. Functional and global health status scales indicated towards better levels of functioning, whereas higher scores in the symptom scales demonstrated higher levels of symptoms.	At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU
Secondary	Quality of life as measured by H&N 35	Rated on a Likert-type scale from one (never) to four (almost always). Multi-item scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), and six symptom items (teeth problems, opening mouth, dry mouth, sticky saliva, coughing, and feeling ill). Higher scores in the symptom scales demonstrated higher levels of symptoms.	At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU
Secondary	Quality of life as measured by the EQ5D,	Domains: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. It also includes a VAS regarding patients' "Health Today" scored between 0 and 100. Each domain will be converted into categorical values (problems vs no problems).	At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU
Secondary	Quality of life as measured by the cancer worry scale (CWS)	Rated on a Likert-type scale from one (never) to four (almost always), which were summed to produce a total CWS score ranging from 8 to 32, with higher scores indicating more frequent worries about cancer.	At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU
Secondary	Quality of life as measured by the IT questionnaire	Rated on a Likert-type scale from one (never) to four (almost always), to evaluate toxicity after immunotherapy treatment.	At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU
Secondary	Quality of life as measured by the sexuality questionnaire	Rated on a Likert-type scale from one (never) to four (almost always), to evaluate problems in sexual functioning.	At baseline, at surgery (week 4) and after 3, 6, 9, 12, 18 and 24 months during FU